Does protein aggregation drive postmitotic tissue degeneration?
Jeffery W. Kelly
Abstract
Pharmacological evidence, from clinical trials where patients with systemic amyloid diseases are treated with disease-modifying therapies, supports the notion that protein aggregation drives tissue degeneration in these disorders. The protein aggregate structures driving tissue pathology and the commonalities in etiology between these diseases and Alzheimer's disease are under investigation.
Topics & Concepts
Degeneration (medical)Protein aggregationMedicineDiseasePathologyEtiologyAmyloid (mycology)BioinformaticsNeuroscienceBiologyBiochemistryAmyloidosis: Diagnosis, Treatment, OutcomesAlzheimer's disease research and treatmentsEndoplasmic Reticulum Stress and Disease